Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 02, 2026
TSLL's +26% Rebound: What Powered the Leveraged Tesla ETF Higher

TSLL's +26% Rebound: What Powered the Leveraged Tesla ETF Higher

Key Takeaways

  • TSLL gained roughly 26% over the last 30 days, rebounding sharply from a late-July low near $7.24 to a recent close around $9.09.
  • The fund is a leveraged single-stock ETF that targets 200% of the daily return of Tesla, Inc. (TSLA) before fees and expenses.
  • The rally was driven by Tesla's recovery from its post-earnings selloff, supported by strong China deliveries, easing labor tensions, and renewed optimism around autonomy, robotics, and energy storage.
  • Despite the 30-day rebound, TSLL remains sharply lower over the trailing quarter, reflecting Tesla's margin compression and the compounding effect of daily-reset leverage.
  • Leveraged single-stock ETFs carry elevated volatility and are designed for short-term trading horizons rather than long-term buy-and-hold positioning.

TSLL Structure and How It Delivers Exposure

TSLL seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of Tesla's common stock. The fund is non-diversified and invests at least 80% of its net assets in Tesla securities and financial instruments such as total-return swap agreements and options that provide leveraged exposure. Launched in August 2022, the fund carries a net expense ratio of approximately 0.83% and ranks among the most actively traded leveraged single-stock ETFs. I also checked this using Tickeron’s AI Screener to see how the fund compares with other vehicles in the space.

Unlike a diversified equity fund, TSLL is effectively a pure expression of Tesla's single-name price action. Its holdings consist primarily of Tesla total-return swaps alongside U.S. Treasury securities, government money-market funds, and cash used as collateral. Sector exposure is concentrated entirely in consumer discretionary, because the fund's economic exposure is tied to one issuer. This structure means TSLL's performance is essentially a leveraged version of Tesla's daily moves, magnified by the effects of daily rebalancing.

Recent Price Action: 30 Days Compared With the Quarter

Over the last 30 days, TSLL rose approximately 26%, climbing from a closing price near $7.24 to roughly $9.09. The move was driven by Tesla, whose shares advanced about 13% over the same span from the low $300s to the mid-$300s. Because TSLL seeks twice Tesla's daily return, its rebound was roughly double the underlying stock's gain, though daily rebalancing means the relationship is not exact over longer windows.

The broader picture over the last quarter is markedly different. Tesla shares declined roughly 19% during the period, falling from the mid-$430s to the low-$350s, while TSLL fell about 42%. That decline of more than twice the underlying stock's move reflects the well-documented volatility drag of daily-reset leveraged products: in choppy or falling markets, the compounding of daily returns can cause leveraged ETFs to underperform a simple multiple of the underlying asset's return over multi-day periods.

Factors Behind the 30-Day Advance

TSLL's 30-day advance mirrors a relief rally in Tesla following a sharp post-earnings drawdown. Tesla's second-quarter results delivered record revenue and vehicle deliveries, but adjusted earnings per share missed consensus, operating margin narrowed to roughly 1.4%, and free cash flow turned negative as capital expenditures accelerated. The stock dropped sharply the day after the report and extended its decline to a 52-week low below $300 before buyers re-emerged.

The subsequent recovery was supported by several factors. Strong China wholesale sales, which rose nearly 38% year over year in July, provided a counterweight to concerns about demand and competition. The resolution of a multi-year Swedish labor dispute removed an operational overhang, while management's commentary on full self-driving adoption, robotaxi expansion, and energy-storage deployment helped reframe the narrative around long-term growth. Cooling Treasury yields and a modest rotation back into mega-cap growth names also aided the rebound. Because TSLL amplifies each of these daily moves, it captured the upside with greater intensity than Tesla itself.

Drivers of the Quarterly Decline

The last quarter's decline traces primarily to a repricing of Tesla's near-term profitability. Rising research and development and capital-spending commitments—with full-year capital expenditure guidance above $25 billion tied to AI infrastructure, robotics, and autonomous-vehicle programs—compressed margins and pushed free cash flow into negative territory. Investor attention shifted from unit-volume growth toward margin durability and the pace of returns on heavy investment.

Institutional positioning and sector rotation also played a role, as elevated valuations across the consumer-discretionary and growth complex came under pressure. Tesla's slide from the mid-$400s toward the low $300s translated into an outsized decline for TSLL because of its 2x daily leverage. This underscores why leveraged single-stock ETFs are generally used as tactical, short-horizon instruments: their multi-day and multi-week returns can diverge materially from a simple multiple of the underlying stock.

Looking Ahead at Key Watchpoints

Going forward, TSLL's trajectory will remain tightly linked to Tesla's fundamentals and to the same macro forces that drive mega-cap growth equities. Key factors to monitor include the pace of margin recovery and the trajectory of operating expenses, the company's ability to fund its AI and robotics roadmap without further eroding free cash flow, and the durability of demand in China and other major markets. Regulatory developments around full self-driving and robotaxi deployment, along with any progress on autonomy commercialization, represent both potential catalysts and sources of headline risk.

At the macro level, interest-rate expectations and inflation trends will continue to influence valuations across high-multiple growth names. Broader sector rotation, institutional ETF flows, and shifts in risk appetite can amplify Tesla's moves—and therefore TSLL's—in either direction. Because of its daily-reset leverage, TSLL is best understood as a tactical tool for experienced traders, with performance over any period longer than a single day subject to compounding effects that can diverge sharply from the underlying stock. I also checked this using Tickeron’s AI Screener to monitor comparable setups.

Tickeron AI Screener in Practice

In my own analysis, Tickeron’s AI Screener serves as a practical way to scan for patterns and signals across leveraged products and related names. It helps surface technical and fundamental filters that can inform how a vehicle like TSLL fits into broader market conditions without replacing core due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TSLL

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


TSLL sees its Stochastic Oscillator climbs out of oversold territory

On October 02, 2026, the Stochastic Oscillator for TSLL moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 46 instances where the indicator left the oversold zone. In 42 of the 46 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on TSLL as a result. In 60 of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

TSLL moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TSLL crossed bullishly above the 50-day moving average on September 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSLL advanced for three days, in 248 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 172 of 183 cases where TSLL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TSLL turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 32 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSLL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

TSLL broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Tesla (NASDAQ:TSLA).

Industry description

The investment seeks daily investment results, before fees and expenses, of 200% of the daily performance of TSLA. The fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of TSLA and financial instruments, such as swap agreements and options, that provide leveraged exposure to TSLA. The fund is non-diversified.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily TSLA Bull 2X ETF (TSLL) ETF was 8%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 10%. TSLA experienced the highest price growth at 6%, while TSLA experienced the biggest fall at 6%.
View a ticker or compare two or three
TSLL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
TSLL's +26% Rebound: What Powered the Leveraged Tesla ETF Higher